BOSTON, Sept. 21, 2011 /PRNewswire/ -- Summer Street Research Partners is pleased to announce the recent closing of a financing for Sunshine Heart (ASX: SHC). Sunshine Heart is a Minnesota-based medical device company that is developing the C-Pulse® Heart Assist System, an implantable, non-blood contacting, heart assist therapy for the treatment of moderate to severe heart failure which can be implanted using a minimally invasive procedure.
Sunshine Heart raised a total of A$7.4 million primarily from institutional investors in the U.S., Canada, and Australia. Summer Street Research Partners served as the exclusive U.S. placement agent for the transaction. "Summer Street Research is very excited to be involved with Sunshine Heart, an innovative company in the cardiac device space. We are delighted to assist them with this financing and the interest from high quality fundamental healthcare investors," said Al Sollami, CEO of Summer Street Research Partners.
Summer Street Research Partners is an investment banking, institutional equity research and trading firm that focuses exclusively on the healthcare sector. Our mission is to help our clients maximize returns by providing the best healthcare research, ideas and investment opportunities. The firm was founded in 2002, with a culture of providing a proprietary equity research product, utilizing more than 10,000 physicians and industry professionals provided through MCRI, a division of Summer Street Research Partners. www.ssrp.com
Matthew H. Dormer
Director, Investment Banking
Summer Street Research Partners
SOURCE Summer Street Research Partners